Federal Health Official Placed on Administrative Leave Amid Ethics Scrutiny Over Conflicts of Interest
The Department of Health and Human Services (HHS) has placed Alicia Jackson, the director of the Advanced Research Projects Agency for Health (ARPA-H), on administrative leave following reports that she maintained significant financial ties to the private sector while advocating for policies that could benefit her personal investments. Jackson, who founded the menopause-focused telehealth platform Evernow before joining the federal government, had been a vocal proponent of removing “black box” warnings from hormone replacement therapy (HRT) medications—a move that industry analysts suggest could significantly expand the market for platforms like the one she helped establish.
The controversy centers on Jackson’s dual role as a federal gatekeeper for biomedical research funding and as a private investor with a multi-million-dollar portfolio. Disclosure records indicate that Jackson retained at least $115,000 in Evernow stock and various stock options upon entering public service, alongside a broader portfolio of holdings that potentially intersect with the $1.5 billion budget and research initiatives she oversees at ARPA-H.
A Chronology of Policy and Personal Interests
The decision to remove the black box warnings—the most stringent safety labeling required by the Food and Drug Administration (FDA)—was announced last November. The policy change was framed by HHS officials as a major step toward de-stigmatizing menopause care. Jackson, standing before an HHS-branded lectern at a press conference, lauded the decision, declaring, “Today we have the opportunity to add up to a decade of healthy years to the life of every woman that you love. The science is clear: Hormone therapy is safe and effective.”
While the FDA’s own advisory panels had signaled a shift in perspective on HRT warnings months prior to Jackson’s arrival in government, her public endorsement of the move occurred while her financial disclosures remained uncertified and her personal ties to the telehealth sector were still intact. By the following spring, Evernow had initiated a nationwide expansion, a move that coincided with the broader regulatory easing that Jackson had championed.
The timeline of Jackson’s tenure reveals a pattern of delayed or incomplete ethical documentation. Despite taking office on October 20, 2025, her mandatory financial disclosures from October 2025 and mid-2026 remained uncertified by agency ethics officials. This lack of certification, according to legal experts, points to a breakdown in the institutional oversight mechanisms designed to prevent exactly this type of conflict.
The Scope of Financial Entanglements
Jackson’s financial profile, detailed in records recently added to the ProPublica Trump Team Financials database, suggests a complex web of investments that go far beyond her startup roots. Her holdings include more than 60 venture capital and private equity funds, many of which do not publicly disclose their underlying assets.
Of particular concern to ethics watchdogs is her stake in Gameto Inc., a biotechnology firm currently engaged in a $10 million, two-year project funded by ARPA-H. While the grant was awarded before Jackson’s appointment, the value of her investment in the company grew from a range of $15,001–$50,000 in October 2025 to $50,001–$100,000 by August 2026. Furthermore, her husband, venture capitalist Alex Jacobson, holds a significant position at 137 Ventures, a firm with extensive investments in digital health and medical devices—entities that often seek government grants.
The oversight of these assets is further complicated by a draft waiver obtained by Bloomberg Law, which would have permitted Jackson to participate in decisions affecting 30 of her investments, including Palantir Technologies. Palantir, which holds a multimillion-dollar contract with ARPA-H for data infrastructure, saw that contract extended by one year in June 2026 for approximately $13.7 million. Although the draft waiver exists, it is unclear if it was ever formally granted, and the Office of Government Ethics has not publicly listed Jackson as a recipient of any such exemption.
Official Responses and the State of Ethics Oversight
The response from the federal government has been measured but pointed. An HHS spokesperson confirmed that Jackson is currently on administrative leave, stating, “HHS requires all officials to comply with federal ethics laws, regulations, and policies.” However, the agency has remained silent on whether an Inspector General investigation is underway or why the initial ethics waivers were never finalized.
Ethics experts argue that the situation reflects a broader erosion of institutional standards. Virginia Canter, who served as an ethics lawyer under four presidencies, described the situation as “alarming” and potentially in violation of federal statutes that prohibit government employees from participating in matters where they have a financial interest. “We should care because her company is apparently intending to profit off this change in policy that she endorsed as a government official while still retaining a financial interest in the company,” Canter noted.
The capacity for agencies to monitor these conflicts has been severely diminished. A recent analysis by the Campaign Legal Center found that HHS has seen its full-time ethics staff reduced by nearly 30% over the last year. This reduction in personnel has led to a significant increase in the number of missed or unfiled financial disclosures across the executive branch, with nearly 420 reports left unfiled by Trump appointees last year—a fourfold increase compared to the previous administration.
Broader Implications for Public Trust
The case of Alicia Jackson is part of a larger trend of scrutinized financial disclosures involving senior federal officials. Similar concerns have been raised regarding Health Secretary Robert F. Kennedy Jr., whose wife’s media company, Youngster Productions, received consulting fees from “MAHA Action,” a nonprofit promoting Kennedy’s policy agenda. These revelations have prompted calls for deeper investigations into whether private financial gain is influencing the prioritization of the “Make America Healthy Again” policy initiatives.
Similarly, the Department of Justice has faced criticism over the crypto-related holdings of Attorney General Todd Blanche, who previously held significant assets in digital currencies while his department oversaw regulatory investigations into that same industry. Across the board, these instances highlight the tension between the recruitment of private-sector experts into government roles and the stringent requirements of public service.
The implications for ARPA-H are particularly significant. As a relatively new agency with a mandate to pursue “revolutionary” biomedical research, its credibility depends on the impartiality of its leadership. If the public perceives that funding decisions or regulatory shifts are steered by the personal investment portfolios of its directors, the agency’s ability to secure broad-based support for its multi-billion-dollar initiatives may be compromised.
Moving Forward
As the investigation into Jackson’s conduct continues, the fundamental question remains whether the current federal ethics framework is robust enough to handle the intersection of high-stakes venture capital and government policy. The reliance on voluntary recusal and the slow pace of ethics certification present significant risks to the integrity of the administrative state.
For now, the administrative leave of the ARPA-H director serves as a warning to other appointees. Without transparent and enforced ethics agreements, the line between fostering innovation and personal profit remains dangerously thin. Whether Jackson’s departure from her duties is a temporary setback or a permanent exit remains to be determined by the ongoing internal reviews, but the incident has already served as a catalyst for a renewed debate in Washington regarding the necessity of total divestment for those holding the levers of federal research and development funding.
The data provided by the latest round of financial disclosures underscores a systemic issue: as more private-sector figures enter the government, the pressure on ethics offices to monitor and enforce compliance has reached a breaking point. Without a significant reinvestment in the staff and processes responsible for transparency, the potential for conflicts of interest—and the resulting public erosion of trust—is likely to persist.
